

***Fiscal Year 2017 Amyotrophic Lateral Sclerosis Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Therapeutic Development Award</b></p> <p><b>Go to:</b>  <a href="#">Program Announcement</a>  <a href="#">General Application Instructions</a></p> <p><b>Grants.gov Funding Opportunity Number:</b>  <a href="#">W81XWH-17-ALSRP-TDA</a></p>	<p>Independent investigators at all academic levels</p>	<ul style="list-style-type: none"> <li>• <b>Pre-application is required; full application submission is by invitation only.</b></li> <li>• Supports post-discovery, preclinical development of therapeutics for ALS</li> <li>• Preliminary data, including identify and purity of an identified bioactive compound(s), are required</li> <li>• Types of efforts that will be supported include: <ul style="list-style-type: none"> <li>○ Validation of lead pharmacological agents up to IND submission</li> <li>○ Optimization of potency and pharmacology, studies of formulation, stability and production methods based on Good Manufacturing Practices</li> </ul> </li> <li>• Collaboration with industry is encouraged</li> <li>• Clinical trials are not allowed</li> <li>• Does not support screening or development of screens or models</li> </ul>	<ul style="list-style-type: none"> <li>• Maximum period of performance is 2 years.</li> <li>• Maximum funding of \$1,000,000 for direct costs</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application:</b>  June 9, 2017  5:00 p.m. Eastern Time (ET)</p> <p><b>Application:</b>  August 31, 2017  11:59 p.m. ET</p>
<p><b>Therapeutic Idea Award</b></p> <p><b>Go to:</b>  <a href="#">Program Announcement</a>  <a href="#">General Application Instructions</a></p> <p><b>Grants.gov Funding Opportunity Number:</b>  <a href="#">W81XWH-17-ALSRP-TIA</a></p>	<p>Independent investigators at all academic levels</p>	<ul style="list-style-type: none"> <li>• <b>Pre-application is required; full application submission is by invitation only.</b></li> <li>• Supports hypothesis-driven drug discovery efforts focused on ALS therapeutics</li> <li>• Preliminary data are not required</li> <li>• Types of efforts that will be supported include: <ul style="list-style-type: none"> <li>○ Novel exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and/or advancing a novel treatment modality</li> <li>○ Development, validation and use of novel of high-throughput screens and model systems based on novel targets or innovative drug systems</li> <li>○ Development of methods for measuring engagement of mechanistic targets by drug candidates</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>2</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$500,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application :</b>  June 9, 2017  5:00 p.m. ET</p> <p><b>Application:</b>  August 31, 2017  11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"><li>• Innovation in technologies and techniques is an important criteria</li><li>• Characterization of mechanisms for the purpose of identifying new targets is outside of the scope of this announcement</li></ul>		